Opin vísindi
→
Fletta eftir efnisorði

Fletta eftir efnisorði "Outcomes research"

Atriði 1-4 af 4

Development of classification criteria for hand osteoarthritis : Comparative analyses of persons with and without hand osteoarthritis

Haugen, Ida K.; Felson, David T.; Abhishek, Abhishek; Berenbaum, Francis; Bierma-Zeinstra, Sita; Borgen, Tove; Herrero Beaumont, Gabriel; Ishimori, Mariko; Jonsson, Helgi; Kroon, Féline P.B.; Maheu, Emmanuel; Ramonda, Roberta; Ritschl, Valentin; Stamm, Tanja A.; Van Der Heijde, Desirée; Wittoek, Ruth; Greibrokk, Elsie; Smeets, Wilma; Kloppenburg, Margreet (2020-06-25)

Objectives Further knowledge about typical hand osteoarthritis (OA) characteristics is needed for the development of new classification criteria for hand OA. Methods In a cross-sectional multi-centre international study, a convenience sample of patients ...
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration

Michelsen, Brigitte; Lindström, Ulf; Codreanu, Catalin; Ciurea, Adrian; Zavada, Jakub; Loft, Anne Gitte; Pombo-Suarez, Manuel; Onen, Fatos; Kvien, Tore K; Rotar, Ziga; Santos, Maria Jose; Iannone, Florenzo; Hokkanen, Anna-Mari; Gudbjornsson, Bjorn; Askling, Johan; Ionescu, Ruxandra; Nissen, Michael J; Pavelka, Karel; Sanchez-Piedra, Carlos; Akar, Servet; Sexton, Joseph; Tomsic, Matija; Santos, Helena; Sebastiani, Marco; Österlund, Jenny; Geirsson, Arni Jon; Macfarlane, Gary; van der Horst-Bruinsma, Irene; Georgiadis, Stylianos; Brahe, Cecilie Heegaard; Ørnbjerg, Lykke Midtbøll; Hetland, Merete Lund; Østergaard, Mikkel (BMJ, 2020-09-01)

OBJECTIVES: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) ...
Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible

Palsson, Olafur; Löve, Þorvarður Jón; Gunnarsdóttir, Anna Ingibjörg; Gunnarsson, Pétur Sigurður; Rúnarsdóttir, Eydís Erla; Krogh, Niels Steen; Gudbjornsson, Bjorn (BMJ, 2019-07)

Objectives To determine in a retrospective cohort whether patients with psoriatic arthritis (PsA) who would not have fulfilled the inclusion criteria for randomised controlled trials (RCTs) for the TNF inhibitor (TNFi) chosen for their treatment (excl) ...
Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis

Lindström, Ulf; Glintborg, Bente; Di Giuseppe, Daniela; Nordström, Dan; Aarrestad Provan, Sella; Gudbjornsson, Bjorn; Askling, Johan; Hetland, Merete Lund; Aaltonen, Kalle; Krogh, Niels Steen; Geirsson, Árni J.; Jacobsson, Lennart (BMJ, 2019-10)

Objective Although clinical trials support equivalence of originator products and biosimilars for etanercept and infliximab, real-world studies among biologics-naïve patients with spondyloarthritis (SpA) are lacking. The objectives were to compare ...

Atriði 1-4 af 4

Leita

Fletta

Opin vísindi
- Efnisflokkar
- Höfundar
- Titlar
- Efnisorð
- Deildir
- Svið
- DOI
- Titill tímarits

Fletta eftir efnisorði "Outcomes research"

Fletta eftir efnisorði "Outcomes research"

Leita

Fletta

Opin vísindi

Um vefinn

Reikningurinn minn